Pharma Stock in Focus After Board Approves Buyback of Shares Worth ₹800 Cr

Synopsis: The Hyderabad-based pharma giant has given the green light to repurchase shares at ₹1,475 each, a 10% premium over the current market price.

 A major Indian pharma giant board approved a ₹800 crore share buyback on April 6, offering shareholders ₹1,475 per share, about 10.9% above the market price. The tender offer covers up to 54 lakh shares, with April 17 set as the record date. It is a clear signal that the company is in good financial health and wants to reward its investors.

With a market cap of Rs. 77,836 Crore, the shares of Aurobindo Pharma Ltd. is currently trading at ₹1,340.00, up 0.47%. Following an ₹800 crore buyback announcement at ₹1,475, the stock reached an intraday high of ₹1,357.90 before settling. It touched an intraday low of ₹1,318.50 earlier in the session. 

What just happened?

On the morning of April 6, 2026, Aurobindo Pharma’s board met and officially approved a share buyback programme. The company will spend up to ₹800 crore to buy back its own shares from existing shareholders at ₹1,475 per share — through the tender offer route. This means shareholders get to submit their shares directly to the company at the set price, which is higher than what the stock was trading at in the open market.

The announcement had been in the works for a few days. When the company first announced the board meeting on April 1, the stock jumped 4% and hit a 52-week high of ₹1,355.50 on the NSE, as investors expected good news. The buyback was that confirmation.

The numbers, explained simply

Aurobindo wants to buy back up to 54,23,728 shares at a price of ₹1,475 each, with the total spend capped at ₹800 crore. These shares represent just 0.93% of the company’s total paid-up equity share capital – a relatively small slice, but a meaningful one in terms of capital returned to shareholders. Each share has a face value of ₹1, so the buyback price is a significant premium over the nominal value.

In terms of the company’s overall finances, the ₹800 crore outlay equals 3.93% of its total funds on a standalone basis, and 2.62% on a consolidated basis. The buyback is being done through the tender offer route, and the record date has been fixed as April 17, 2026, the date that determines which shareholders are eligible to participate. The board also has the flexibility to increase the buyback price and buy fewer shares – as long as the total spend does not exceed ₹800 crore. This flexibility can be exercised up to one working day before the record date.

What does this mean for the shareholding pattern?

Right now, promoters hold 51.82% of Aurobindo Pharma’s total equity shares, that’s out of a total 58.08 crore shares as of December 31, 2025. The remaining 48.18% is held by public shareholders including, institutional investors, and others.

When a buyback happens through the tender route, shares from public shareholders are bought back first (proportionally). This means the total number of shares in the market goes down. If promoters choose not to participate,which is common – their percentage stake automatically increases, even without buying a single new share.

In simple terms: fewer shares outstanding plus the same promoter holding equals a higher promoter percentage. The exact post-buyback shareholding pattern will only be known once the process is complete.

What should shareholders do now?

If you hold Aurobindo Pharma shares, the key date to mark on your calendar is April 17, 2026 – the record date. You must hold shares on this date to be eligible to participate in the buyback. Once the company announces the tender offer schedule, eligible shareholders will receive details on how many shares they can submit and by when.

Keep in mind that participation is not mandatory. You can choose to hold your shares if you believe the stock will go higher than the buyback price of ₹1,475 in the future. That’s a personal investment call.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stock in Focus After Board Approves Buyback of Shares Worth ₹800 Cr appeared first on Trade Brains.